| 摘要: |
| ［摘要］ 2025年5月，Diabetes Care杂志发表了美国糖尿病学会专家共识《糖尿病患者代谢功能障碍相关脂肪性肝病（MASLD）：筛查和早期干预的必要性》。该共识阐述了MASLD命名变更的原因、如何进行风险分层、当前的治疗和长期监测、多学科专业团队管理的重要性等。该文结合近期国内外关于糖尿病合并MASLD的专家共识与临床指南对该共识进行解读，以期提高对MASLD及其相关疾病风险的认识，及早筛查、诊断、治疗和规范管理合并MASLD的糖尿病前期和2型糖尿病患者。 |
| 关键词: 代谢功能障碍相关脂肪性肝病 肝纤维化 肝硬化 糖尿病前期 糖尿病 |
| DOI：10.3969/j.issn.1674-3806.2026.02.03 |
| 分类号: |
| 基金项目:河北省医学科学研究课题（编号：20241865） |
|
| The need for screening and early intervention of metabolic dysfunction-associated steatotic liver disease in diabetes patients: an interpretation on the consensus of the American Diabetes Association |
|
WANG Yun1, XU Zhangrong2, ZHANG Lili3*
|
|
1.Department of Endocrinology, the Second Hospital of Shijiazhuang, Shijiazhuang 050051,China; 2.Department of Endocrinology, the Ninth Medical Center, Chinese PLA General Hospital, Beijing 100101,China; 3.Hebei Provincial Key Laboratory of Basic Medicine for Diabetes, the Second Hospital of Shijiazhuang, Shijiazhuang 050051, China
|
| Abstract: |
| ［Abstract］ In May 2025, Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) in People with Diabetes: the Need for Screening and Early Intervention. A Consensus of the American Diabetes Association, was published in Diabetes Care. This consensus elaborates on the reasons for nomenclatural changes in MASLD, how to conduct risk stratification, current treatments and long-term monitoring and the importance of managements of MASLD by a multi-disciplinary professional team. In this paper, the authors interpret this consensus by combining the recent expert consensuses and clinical guidelines on diabetes complicated with MASLD at home and abroad, hoping to improve the understanding of MASLD and the disease risks associated with MASLD, and to screen, diagnose, treat and standardly manage prediabetes and type 2 diabetes mellitus(T2DM) patients complicated with MASLD at an early stage. |
Key words: Metabolic dysfunction-associated steatotic liver disease(MASLD) Liver fibrosis Liver cirrhosis Prediabetes Diabetes
*共同通信作者 |
